Upcoming Webinar :Register now for 'ULIP as an investment during economic recovery' powered by Bajaj Allianz
you are here: HomeNewsBusiness

Deloitte To Shut 4 Offices, To Transfer All Staff To Permanent Work From Home

Deloitte on October 17 informed staff it will shut offices in Southampton, Nottingham, Liverpool and Gatwick, which together employ 500

Oct 22, 2020 / 11:30 AM IST

Deloitte (Image: Moneycontrol)


Deloitte will close down 4 of its 50 British offices and retain all of the employees on permanent work-from-home contracts – a move aimed at managing real estate expenses amid the COVID-19 pandemic.

Deloitte, on October 17, informed staff it will shut offices in Southampton, Nottingham, Liverpool and Gatwick, which together employ 500, The Economic Times reported.

The consulting and accounting firm’s UK managing partner Stephen Griggs in an email said the pandemic has “fast tracked our future work programme, leading us to review our real estate portfolio.” He also assured staff that this would not affect Deloitte’s presence in these regions.

Follow our LIVE Updates on the coronavirus pandemic here

This comes after the company, in April, announced 20 percent pay cut for all partners at its British businesses as an alternative to job cuts.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
Demand for office space has nosedived amid the COVID-19 pandemic as millions began working from due to quarantines, lockdowns and to keep social distancing norms.
Moneycontrol News
first published: Oct 22, 2020 11:30 am

stay updated

Get Daily News on your Browser
Sections